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The p53 protein is stabilized during infection of primary human fibroblasts with human cytomegalovirus (HCMV). However, the p53 in
HCMV-infected cells is unable to activate its downstream targets. HCMVaccomplishes this inactivation, at least in part, by sequestering p53 into
viral replication centers within the cell's nucleus soon after they are established. In order to better understand the interplay between HCMV and
p53 and the mechanism of sequestration, we constructed a panel of mutant p53-GFP fusion constructs for use in transfection/infection
experiments. These mutants affected several post-translational modification sites and several sites within the central sequence-specific DNA-
binding domain of the protein. Two categories of p53 sequestration were observed when the mutant constructs were transfected into primary
fibroblasts and then infected at either high or low multiplicity. The first category, including all of the post-translational modification mutants,
showed sequestration comparable to a wild-type (wt) control, while the second category, mutants affecting the DNA-binding core, were not
specifically sequestered above control GFP levels. This suggested that the DNA-binding ability of the protein was required for sequestration.
When the HCMV genome was analyzed for p53 consensus binding sites, 21 matches were found, which localized either to the promoters or the
coding regions of viral proteins involved in DNA replication and processing as well as structural proteins. An analysis of in vivo binding to these
identified sites via chromatin immunoprecipitation assays revealed differential binding to several of the sites over the course of infection.
© 2005 Elsevier Inc. All rights reserved.Keywords: p53; Human cytomegalovirus; DNA-binding domain; Sequestration; In vivo binding assaysIntroduction
As a key player in cellular damage response, p53 is stabilized
and activated in the uninfected cell after several potentially
damaging events including UVor γ ray irradiation, exposure to
extreme heat, hypoxia, or starvation, and after viral infection
(Ko and Prives, 1996). Activation of p53 can lead to either cell
cycle arrest, presumably to allow repair of damaged DNA, or to
apoptosis. p53 mediates control of these two outcomes by
sequence-specific DNA-binding and transactivation of specific
target genes including: p21/WAF1/CIP, 14-3-3a, GADD45, and
PCNA for arrest, and Bax, Noxa, PERP, PIG3, and Fas for⁎ Corresponding author. Fax: +7 208 885 6518.
E-mail address: lfort@uidaho.edu (E.A. Fortunato).
0042-6822/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.12.013apoptosis (reviewed in Sax and El-Deiry, 2003). Another
principal target of p53 is HDM2, an E3 ubiquitin ligase that
works in an autoregulatory feedback loop to tightly control
levels of p53 within the cell (Juven et al., 1993). Although
primarily regarded as an activator of transcription, p53 can also
act as an inhibitor or repressor when bound to its target DNA,
particularly, when the pathway of choice leads to apoptosis
(Hoffman et al., 2002; Mirza et al., 2003; Miyashita et al., 1994;
Murphy et al., 1996).
There is also increasing evidence that p53 may directly
influence DNA repair. This may be by first binding to damaged
regions of DNA in a nonspecific manner with its C-terminal
domain (Zotchev et al., 2000) and then recruiting repair
machinery to the site via protein/protein interactions. In
support of this concept, p53 directly interacts with several
proteins involved in nucleotide excision repair, homologous
20 K. Rosenke et al. / Virology 348 (2006) 19–34recombination, and mismatch repair including the excision
repair proteins XPB and XPD (Wang et al., 1995), CSB (Wang
et al., 1995), and RPA (Dutta et al., 1993), the recombination
proteins BRCA1 (MacLachlan et al., 2002), RAD51 (Sturzbe-
cher et al., 1996), BLM (Wang et al., 2001), and WRN
(Blander et al., 1999), and the mismatch protein MSH2 (Zink
et al., 2002). There is also evidence that the p53 protein can
directly upregulate the levels of both the p48 subunit of the
XPE protein and the XPC protein, which are both involved in
UV dimer recognition in nucleotide excision repair (Adimoo-
lam and Ford, 2003; Hwang et al., 1999).
The p53 protein is post-translationally modified via
phosphorylation and acetylation upon cellular stress. Phosphor-
ylation can occur in both the N-terminal transactivation domain
and the C-terminal domain involved in nonspecific binding to
the DNA, whereas acetylation and sumoylation primarily occur
in the C-terminal region (reviewed in Xu, 2003). It is thought
that these modifications aid in stabilizing the protein, protecting
it from ubiquitination and degradation via HDM2 (reviewed in
Liu and Kulesz-Martin, 2001; Xu, 2003). In addition, the C-
terminal modifications are thought to potentially enhance
transactivation and the sequence-specific DNA-binding ability
of the central core of the protein, although there is some
controversy as to the importance of these modifications in vivo
(Prives and Manley, 2001). The core sequence-specific DNA-
binding domain contains several key residues that contact the
DNA directly, and it is this region that is most heavily mutated
in human cancers involving modifications to the p53 protein
(Ko and Prives, 1996).
Our interest in p53 stems from the fact that elevated steady
state levels of p53 are observed in HCMV-infected fibroblasts
(Jault et al., 1995; Muganda et al., 1994), vascular smooth
muscle cells (Speir et al., 1994), HUVECs (Kovacs et al.,
1996), and astrocytes (Lokensgard et al., 1999) by 24 h post
infection (pi). However, p53 cellular targets are not activated
after infection (Bresnahan et al., 1996; Jault et al., 1995).
Like several other viruses (Chung et al., 2003; Debbas and
White, 1993; Jenkins et al., 1988; Jeong et al., 2004;
Meertens et al., 2004; Scheffner et al., 1990; Wang et al.,
1994; Werness et al., 1990; Zantema et al., 1985), HCMV
encodes a protein, IE86, which can interact with p53 in vitro
and in in vivo overexpression assays (Bonin and McDougall,
1997; Muganda et al., 1994, 1998; Song and Stinski, 2005;
Speir et al., 1994; Tsai et al., 1996; Wang et al., 2000). There
are several examples in the literature where transient
expression of IE86 has disrupted the activation of p53
cellular targets (Castillo et al., 2000; Hsu et al., 2004; Murphy
et al., 2000; Speir et al., 1994; Tsai et al., 1996; Zhu et al.,
1995). Clearly, HCMV has the ability to alter cell fate and
fully “activate” the infected cell without triggering its death.
The literature suggests this may at least in part be due to an
alteration in p53's ability to activate transcription of its
cellular targets. Although IE86 most probably plays a role in
the downregulation of p53, direct interaction between the two
proteins has never been demonstrated during the course of an
infection. We propose that sequestration of p53 into viral
replication centers, which occurs relatively early afterinfection (Fortunato and Spector, 1998), provides a second,
equally likely mechanism for altering p53's activity.
The question of whether or not sequestration of p53 is used
solely as a means to disrupt this protein's cellular interactions,
or in addition, to utilize the transactivation function of this
protein for the benefit of the virus has come to the forefront of
our work. In this paper, we have investigated the mechanism
behind and the importance of HCMV-mediated sequestration of
p53. The experiments described herein were aimed at
determining the critical regions of the p53 protein responsible
for this sequestration phenomenon using site-directed muta-
genesis of key p53 residues. Our results suggest that post-
translational modification sites are dispensable for sequestration
into replication centers, whereas an intact DNA-binding core is
required for sequestration. In support of the idea that p53 may
bind directly to HCMVDNA and in this way be transported into
and tethered within the replication centers, we show that the
HCMV genome contains 21 matches for the p53 consensus-
binding site. Using chromatin immunoprecipitation (ChIP)
analyses, we demonstrate differential binding to several of these
sites during infection, lending credence to the idea that p53 may
also be sequestered by HCMV to utilize its transactivation
function.
Results
Construction and mutagenesis of p53-GFP fusion
protein-expressing plasmids
To test which regions in p53 were important for targeting to
HCMV-induced replication centers after infection, we intro-
duced specific site-directed mutations into the p53 protein at
several residues that are important either for stabilization of the
protein or for DNA binding. Fig. 1 shows a schematic of the
p53 protein delineating the locations of targeted mutations.
The mutants were chosen to represent a cross-section of
different post-translational modification sites as well as sites
that are modified in primary tumors. As there are a large
number of serine residues that can be modified by phosphor-
ylation (reviewed in Xu, 2003), we took advantage of three
previously constructed mutants (Ashcroft et al., 1999). These
mutants change all the serine residues to alanines within the
entire protein. One construct mutates only the serines in the N-
terminus (N term), one only the serines in the C-terminus (C
term), and the final construct encompasses all the serines
encoded in both regions combined (N + C term). Three lysine
residues were mutated to alanines at positions 320, 382, and
386 within the protein. The first two residues are thought to
encode important acetylation sites (Gu and Roeder, 1997; Liu
et al., 1999; Sakaguchi et al., 1998), and the last a site for
sumoylation (Gostissa et al., 1999; Rodriguez et al., 1999),
which is thought to block the addition of ubiquitin and
subsequent HDM2-mediated degradation. Lastly, we generated
six DNA-binding domain mutations commonly found in p53-
related cancers (Bogler et al., 1995). Three of these mutations
appear to solely affect the ability of the protein to interact in a
sequence-specific manner with the target DNA (R175H,
Fig. 1. A schematic representation of the p53 protein showing sites of introduced mutations. The p53 protein is shown with the main functional domains delineated by
different shadings. Above and below the schematic, the sites of mutation are defined. Above the figure, solid bars represent phosphorylation mutants as described in
Ashcroft et al. (1999), and stars in the C-terminal end represent two acetylation and one sumoylation mutant. Below the figure, black diamonds represent several
mutations in the DNA-binding domain core.
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appear, at least in transient transfection assays using an
autologous DNA-binding domain, to also affect the ability of
p53 to transactivate a reporter construct (Raycroft et al., 1990;
Unger et al., 1992).
The procedure for mutant construction is described in detail
in Materials and methods. In order to avoid biased expression
by the strong HCMV major immediate early (IE) promoter, we
generated constructs whose expression was influenced solely by
the endogenous p53 promoter by moving the promoter-p53-
GFP cassette from pCLNCX-p53pro-p53GFP into the multiple
cloning site (MCS) of a modified pCDNA3-T7 vector. This
generated our base construct for mutagenesis, wtp53pCDNA3-
T7. We then used the Stratagene Quickchange mutagenesis kit
to perform site-directed mutagenesis on the wt p53 sequence
within wtp53pCDNA3-T7 using the oligonucleotides outlined
in Table 1. In order to ensure that each of the new mutations that
we chose to introduce was capable of expressing full-lengthTable 1
Mutagenic oligonucleotides used to construct mutant p53-GFP plasmids
Mutant Mutagenic oligo sequence (forward primers)
DNA binding
G154V 5′ CA CCC CCG CCC GTC ACC CGC GTC CG 3′
R175H 5′ AG GTT GTG AGG CAC TGC CCC CAC C 3′
H179Q 5′ TGC CCC CAC CAA GAG CGC TGC TC 3′
N247I 5′ G GGC GGC ATG ATC CGG AGG CCC ATC 3′
R248W 5′ G GGC GGC ATG AAC TGG AGG CCC ATC 3′
R273H 5′ TTT GAG GTG CAT GTT TGT GCC TGT CC 3′
Acetylation/sumoylation
K320R 5′ CC CAG CCA AAG AGG AAA CCA CTG G 3′
K382R 5′ TCC CGC CAT AAA AGA CTC ATG TTC AAG 3′
K386R 5′ AA CTC ATG TTC AGG ACA GAA GGG CC 3′
Phosphorylation
N term S to A mutations at aa 6, 9, 15, 18, 20, 33, 37
C term S to A mutations at aa 315, 371, 376, 378, 392
N + C term All above mutations
The table lists the forward primers used to perform site-directed mutagenesis on
the p53 coding sequence. Mutants are grouped according to the type of site
affected. Forward primer sequences are listed, grouped by amino acid triplets.
The mutagenized nucleotide is in bold italics. For more details on the
phosphorylation mutants, see Ashcroft et al. (1999).fusion protein in vitro, we constructed another set of plasmids
where the p53-GFP fusions were under the control of the T7
promoter in the same parental pCDNA3 plasmid backbone.
Each mutant plasmid produced roughly equivalent amounts of a
full-length p53-GFP fusion protein during in vitro transcription/
translation, which migrated at the expected 80 kDa (53
kDa + 27 kDa GFP; data not shown).
Different groups of p53 mutants show varied sequestration
patterns following transfection/infection
In order to assess whether the virus could sequester our
mutants, we transfected the constructs under the control of the
p53 endogenous promoter into wt fibroblasts and then infected
these cells with HCMV. Low passage KL22 primary foreskin
fibroblasts were seeded onto coverslips and transfected with
each of the mutant constructs, using parallel transfections of wt
p53-GFP and the parental pEGFP-1 plasmid alone as
experimental controls. Following transfection, cells were
infected with the Towne strain of HCMV. The transfections
were performed using Effectine reagent, a lipid-based delivery
system, as it afforded a better efficiency than other methods
tested. As we and others had previously observed that DNA
transfection using Effectine could render cells somewhat
refractory to subsequent infection (D.H. Spector and R. Kaletja
laboratories, personal communications), we wanted to assess
the approximate MOI attained in these experiments. By
comparing transfected/infected cells to several non-transfected
control infections for percentage of IE72+ cells and ppUL44
foci development over the course of infection, we determined
that the Effectine experiments were performed at an MOI of
approximately 0.25 (data not shown). Due to this somewhat
lower MOI, cells were allowed to progress to 96 h pi prior to
harvesting.
Harvested coverslips were stained for the viral processivity
factor ppUL44 to localize the sites of viral replication
(Fortunato and Spector, 1998) and counterstained with Hoechst
dye to visualize the nuclei. In cells transfected with all of the
constructs, including wt p53-GFP and pEGFP-1, we observed
ppUL44+ replication centers of varying numbers and sizes, as
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coverslips from all samples, cells displaying no distinct
foci, multiple small foci, two big foci, and one large focus
could be observed.
Slides were scored in the following manner: coverslips were
stained, mounted, and viewed under 60× magnification to
identify GFP+ cells. Each of the constructs produced easily
discernable GFP+ cells, readily detected over the background
fluorescence of the fibroblasts. When GFP+ cells were found,
the ppUL44 staining was also examined to determine whether
distinct replication center foci were visible within the cell. The
ppUL44 staining therefore served only as a marker for
replication center location. Cells with no distinct ppUL44+
foci were not scored for GFP fusion protein sequestration asFig. 2. Sequestration of mutant constructs can be easily gauged by immunofluoresce
infected at an MOI of approximately 0.25. Cells were allowed to progress for 96 h pi
Ab = 1202S; secondary Ab = donkey anti-mouse couple to TRITC) and analyzed as
Selected results from transfection/infection experiments are shown. The left image f
shows staining for the viral processivity factor ppUL44, which stains only in the replic
to gauge the sequestration of each mutant construct. Panel A represents images take
using confocal microscopy for direct comparison. Post-translational modification mut
show +sequestration for p53 similar to wt p53-GFP. Mutations in the DNA-binding
but instead stain homogeneously throughout the entire nucleus. Scale bar = 5 μm.replication centers were not clearly discernable in these cells.
The number of cells that lacked distinct ppUL44+ foci was
comparable for all constructs tested, including both mutant and
wt p53. The sequestration of the mutant p53-GFP fusion
proteins was always scored in parallel with the wt p53-GFP
construct as the wt construct displayed a clear strong
sequestration pattern for p53-GFP within the replication centers,
regardless of the size of the center (see Figs. 2A and B, wt). We
scored the cells as either having a strong sequestration pattern
comparable to wt (+sequestration), or as having no distinct
specific sequestration, but rather a homogeneous pattern of GFP
staining over the entire nucleus (−sequestration). The back-
ground level was set using transfection of the pEGFP-1 vector
(see Supplemental figure, panel A).nce. Mutant constructs were transfected into KL22 primary fibroblasts and then
, after which coverslips were harvested, fixed, and stained for ppUL44 (primary
described in the text. Only cells exhibiting strong GFP+/ppUL44+ were scored.
or each pair in both panels A and B shows p53-GFP staining. The right image
ation centers of the virus within the nucleus of infected cells. The latter was used
n by epifluorescent microscopy, while panel B shows the same mutants imaged
ants [represented here by N + C term (phosphorylation) and K320R (acetylation)]
domain (represented here by H179Q) show no appreciable sequestration of p53,
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categories: (1) post-translational modifications that occur to
p53 (potentially to stabilize and/or activate the protein) and (2)
mutants in the coding sequence of the sequence-specific DNA-
binding domain. Fig. 2A shows examples of the typical
staining patterns observed for several mutants. The left image
in each pairing shows the pattern of GFP fusion protein
staining, while the right image depicts ppUL44 staining for the
same cell (used to localize the replication centers). It should be
noted here that, regardless of the size of the replication center
foci, the staining pattern observed for each of the mutants
remained constant. We found that sequestration patterns of the
p53-GFP fusion proteins fell within the two categories
described above. The post-translational modification mutant
proteins, whether harboring mutations in phosphorylation,Fig. 3. Mutations in p53 fall into two categories with respect to sequestration. (A) Co
described in the text. After 96 h pi, coverslips were harvested, fixed, and additionally s
ppUL44+ cells were scored. The figure compares the percentage of cells displaying +s
displaying +sequestration when transfected with the wt p53-GFP construct. This com
text for details regarding calculations. Each mutant was tested in at least 2 trials, and, i
Error bars represent one standard deviation. (B) Similar experiments were performed
This allowed subsequent infection at a high MOI of 5. All DNA-binding domain mu
frequencies of +sequestration are calculated as described in the text. Experiments wacetylation, or sumoylation sites, displayed the same percent-
age of cells with +sequestration as the wt fusion protein (as
seen in Fig. 2A and exemplified by mutants N + C term
(phosphorylation) and K320R (acetylation)). However, the
mutant fusion proteins harboring mutations that affected
sequence-specific DNA-binding did not exhibit significant
specific sequestration but instead showed GFP staining over
the entire nucleus (as seen in Fig. 2A and exemplified by
mutant H179Q) and were comparable to the pEGFP-1 control
(see Supplemental figure for EGFP-1 control and additional
examples of mutant protein staining). As the DNA-binding
domain mutants in Group Two often had very strong staining
within the nucleus, we wanted to ensure that we were not
overlooking specific sequestration. We therefore additionally
examined several mutants (from both groups) by confocalnstructs were transfected into KL22 primary fibroblasts followed by infection as
tained for ppUL44 so as to clearly view the viral replication centers. Only GFP+/
equestration when transfected with each of the mutants to the percentage of cells
parison yields a relative frequency of +sequestration for each of the mutants. See
n each trial, 20–50 GFP+/ppUL44+ cells were scored for all mutants and controls.
in FS2 fibroblasts, using electroporation as the method of plasmid introduction.
tants and a select set of Group One mutants were tested in this fashion. Relative
ere performed once.
Fig. 4. All DNA-binding domain mutants are capable of expressing full-length
protein in vivo. Effectine transfection/infection experiments were carried out as
described. Cells were trypsinized, counted, and lysed in LRSB. Equivalent
amounts of cell lysates were electrophoresed on an 8% (A and C) or 10% (B)
SDS-PAGE gel, blotted, and probed for p53 using primary Ab DO-1 followed
by HRP-conjugated goat anti-mouse secondary Ab. Full-length fusion proteins
are delineated with a small arrowhead, whereas endogenous p53 (stabilized by
infection) is indicated by a star. Panel A represents experiments performed in
KL22 cells. The v alone sample in panel B represents KL22 cells infected at an
MOI of 5 and harvested at 96 h pi. Panel C represents experiments performed in
p53−/− fibroblasts.
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mutants shown in panel A to enable direct comparison of the
two imaging methods. Although the confocal images appear
somewhat sharper, the same results were obtained using either
method of microscopy for the DNA-binding domain mutants;
namely, that although some proteins were located within the
replication centers, there was not a specific sequestration into
these sites as there was with either wt p53-GFP or any of the
Group One mutants (see Supplemental figure, panel B, for
more confocal images).
Fig. 3A compares the percentage of cells displaying
+sequestration when transfected with each of the mutants to
the percentage of cells displaying +sequestration when
transfected with the wt p53-GFP construct. The average
percentage of cells exhibiting +sequestration of the wt construct
was calculated using data from 7 trials (for example,
experiment 1 = 18/37 cells displayed +sequestration, experi-
ment 2 = 18/27, etc.; wtav = 0.5). The same calculation was
performed for each mutant construct using data from at least 2
trials (for example, for R175H experiment 1 = 1/40, experiment
2 = 1/30; R175Hav = 0.03). In each trial, 20–50 GFP
+/
ppUL44+ cells were scored for all constructs. The comparison
of mutant to wt yields a relative frequency of +sequestration for
each of the mutants (for example, for R175H 0.03/0.5 = 0.06).
A relative frequency close to zero would indicate that the
mutant was not efficiently sequestered into the replication
centers, whereas a relative frequency close to one would
indicate that the mutant behaved similarly to the wt p53-GFP
construct with respect to sequestration. This figure clearly
demonstrates that post-translational modifications that we
introduced have negligible bearing on the ability of the p53-
GFP fusion protein to be directly sequestered into HCMV
replication centers as all of the Group One mutants (K320R,
K382R, K386R, N term, C term, N + C term) have a relative
frequency of between 0.8 and 1.2 (e.g. very similar to wt).
However, none of the DNA-binding domain mutants (G154V,
R175H, H179Q, N247I, R248W, R273H) demonstrated
significant specific localization to the viral replication centers
(relative frequencies between 0.0 and 0.06), suggesting the
importance of this domain for sequestration.
To rule out the possibility that sequestration patterns
(particularly for the DNA-binding domain mutants) were
due to the low MOI infection conditions or to cell type
specificities, we carried out electroporations of all of the
DNA-binding domain and a select set of the Group One
mutants into different FS2 primary fibroblasts. As electro-
poration does not hinder subsequent infection, we were able
to use an MOI of 5 for these experiments. These infections
proceeded normally, and by 48 h pi, all cells exhibited large,
clearly discernable replication centers as judged by ppUL44
staining. Coverslips were therefore harvested and scored at 48
h pi for GFP fusion protein staining and scoring. Although
performed only one time, the same sequestration patterns
were observed for all of the mutants tested using these high
MOI conditions (Fig. 3B). Therefore, multiplicity of infection
and cell type specificities do not appear to play a role in the
localization of these mutants.p53 DNA-binding domain mutants are expressed as full-length
proteins
As the results we obtained with the DNA-binding domain
mutants were quite dramatic, we wanted to ensure that the lack
of sequestration was not due to a lack of full-length protein
production in vivo. Similar Effectine transfection/infection
experiments were performed as described above, but cells were
harvested to obtain cell lysates, which were used for Western
blot analysis. Shown in Fig. 4A is a representative blot of
lysates prepared from KL22 fibroblasts transfected with each of
the DNA-binding domain mutants and probed for p53. This blot
demonstrates that these cells were capable of expressing full-
length fusion protein (arrowhead) as well as relatively high
levels of the endogenous p53 protein (star; the high endogenous
levels are due primarily to infection-induced stabilization;
Fortunato and Spector, 1998). Since there was so much
endogenous protein in the primary KL22 fibroblasts after
infection (see Fig. 4B), it was hard to assess whether the
mutants were being degraded, possibly contributing to the band
at 50 kDa. We therefore transfected both the wt and all of the
DNA-binding domain mutant constructs into a p53−/− human
fibroblast line (Bunz et al., 1998; Wei et al., 2001). As this is a
knockout cell line, these cells express no endogenous p53
protein, and we could therefore assess the degradation of these
constructs. As can be seen in Fig. 4C, although there may be a
small degree of degradation in these cells, the majority of what
was detected by the p53 Ab was full-length fusion protein
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constructs (G154V and R175H) appeared to show more
degradation in the KL22 cells, this did not occur in the p53−/−
cells. We also performed Western blot analysis on cells infected
for 96 h at high MOI after electroporation with each of the
DNA-binding domain mutants; all mutants displayed full-
length fusion proteins, and no appreciable degradation was
observed for any of the constructs (data not shown). Variations
in protein levels observed in these blots were most likely due to
variations in transfection efficiency, as the percentage of
positive cells varied from transfection to transfection and was
generally quite low, as is typical in primary fibroblasts.
Variations aside, it was clear that each of the binding domain
mutant constructs was expressed as a full-length protein in vivo.
In addition, all Group Two mutants exhibited strongly staining
GFP+ cells whose fusion proteins were not specifically
sequestered (compare the images in Fig. 2 and the Supplemental
figure to Fig. 4).
Formation of heterotetramers is not responsible for
sequestration of exogenous fusion proteins
p53 functions in its active form as a tetramer (reviewed in
Chene, 2001), and several p53 mutants have been shown to be
capable of forming heterotetramers with the wt isoform of the
protein (Chene, 1998; Dridi et al., 2003; Milner and Medcalf,
1991). We therefore wanted to exclude the possibility that the
localization of mutant p53-GFP fusion proteins to the
replication centers was due merely to association with the
endogenous wt protein. To accomplish this, a representative
construct from each predominant subtype of the Group One
mutants (N + C term to represent the phosphorylation and
K320R the acetylation), all of the Group Two DNA-binding
domain mutants and wt p53-GFP as a control were transfected
(using Effectine) into the p53−/− human fibroblasts described
previously (Bunz et al., 1998; Wei et al., 2001). As can be seen
in Fig. 5A, each subtype of mutants displayed a similar pattern
of sequestration in both the normal and the p53−/− fibroblasts
(compare Fig. 5A to Fig. 2).
Fig. 5B graphs the relative frequency of cells showing
specific +sequestration of mutant p53-GFP fusion proteins as
compared to the wt construct in the p53−/− cells as was
described for Fig. 3. As can clearly be seen, the same results
were obtained with and without the presence of an endogenous
wt p53 protein in the cells. These results would indicate that
formation of heterotetramers with endogenous p53 was not
responsible for the sequestration of Group One mutants in the
normal fibroblasts.Fig. 5. Sequestration of mutants occurs in a similar manner in p53−/− cells. (A)
Selected mutant constructs were transfected using Effectine into p53−/− cells and
then infected at an MOI of approximately 0.25. Cells were harvested at 96 h pi
and processed and stained as described in Fig. 2. Epifluorescence microscopy
was used to generate the images shown. Left panels show p53-GFP fusion
protein localization, while right panels are stained for ppUL44. The same three
mutants are shown in this figure and Fig. 2 for direct comparison. (B) Relative
frequencies of +sequestration of selected mutant constructs as compared to the
wt construct, calculated as described in the text and in the legend to Fig. 3.HCMV contains p53-binding sites that are differentially bound
during infection
Our data showing that an intact p53 DNA-binding domain
was required for localization of p53 to ppUL44-containing
Table 2
Potential p53-binding sites within the coding sequence of HCMV
Location of
p53-binding
sites (ORF)
Location of p53-binding
sites in genome
(nucleotides)
Sequence of 1st p53-binding
site consensus match
(PuPuPu C A/T A/T G PyPyPy)
Number of
NT between
sites
Sequence of 2nd p53-binding
site (up to 3 mismatches
in consensus site)
Potential gene(s)
affected
(PuPuPu C A A G PyPyPy)
UL48 65,792–65,801 AAGCAAGCCC 7 GAACTgtCTC UL48
6 cGACcTGTCT
12u GGAcATGCTg
UL48 67,454–67,463 AGACAAGTTC 1 AacCAgGaCT UL48
6 GGACTTGCTg
11u cAACgcGCCC
UL71 104,736–104,745 GGACAAGTTC 6 GGAtcAGgCC UL70, UL71
7 GAtCAgGCCT
3u GGAcATGTTg
UL122/123 172,696–172,705 AGGCAAGTTC 9 cGcCATGgCC UL124, UL121,
UL122/123
14 tGGCcTGACT
3u AGGcgAGCaC
18u AGcCATaaTC
US31 224,014–224,023 GAGCAAGTTC 8 GGAaAcGaCT US31, US32
10 AAACgAcTgC
18u GGcCTctTCC
IGR146 227,000–227,009 AAACAAGTTT 4 AAACATaACg UL36, TRS1
(PuPuPu C A T G PyPyPy)
UL25 31,231–31,240 GGGCATGCTC 18 AGAgATaTgC UL24, UL25
1 cGAgAAGgCC
UL32 42,029–42,038 GGACATGTTT 14 GAGaAgGCCg UL32, UL33
13 cGACAAGgCC
UL55 83,269–83,278 GGACATGTTC 19 AGtCATGTTg UL54, UL55
11 cttCTTGTTT
7u AGtCcAGCgC
UL88 132,803–132,812 GGACATGTTT 11 tGGCcAGCGC UL91, UL88
UL89/93 136,829–136,838 GAACATGTCC 16 cGtCATGCCT UL89, UL93, UL94
12 tGGCAAGTTT
3 cGcCTTGTTT
UL97 142,662–142,671 AGACATGTTT 16 AAGCTgGCgT UL97, UL98
12 GtGCAAGCTg
5u cGACgTGTTC
UL105 155,232–155,241 GGGCATGCTT 1 tcGCATGTgT UL104, UL105
19u AGAtcAGCTC
7u AGACcgGCTC
3u cGGCTccTTC
(PuPuPu C T A G PyPyPy)
UL87 130,447–130,456 GAACTAGCTC 16/17u GAGaAAcCTT UL86, UL87, UL88
12/13u AAcCTTtTCT
(PuPuPu C T T G PyPyPy)
UL4 13,537–13,546 GGACTTGTTC 11 AcGacTGCTC UL2, UL3, UL4
UL45 59,768–59,777 AAACTTGCCC 18 AcACTTtTTg UL44, UL45
16 tGACAcTTTT
19u GcGCcgGCTC
UL54 77,915–77,924 AAACTTGTCC −3 (overlap) GtcCTTGCgC UL54
3u cAcCATGTgC
UL57 87,850–87,859 AAACTTGTCCA 11 cGGCcAGCgC UL58, UL56
13 cGcCcTGCTC
UL64 96,934–96,943 AGACTTGTCC 4/5/6u GAtaTTaTTC UL64, UL65
16u AtAtATGaTC
UL83 120,832–120,841 AAGCTTGCCC 9 AtACTgGCTg UL81, UL82
18u GtGCcgGTCC
7u AGGtgTGTCg
UL122 170,301–170,310 AGACTTGTCC 13 AtGgcTGCCT UL121, UL122
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viral DNA. p53 binds most effectively to DNA as a tetramer to
two adjacent consensus binding sites separated by 0–13
nucleotides and encoding the sequence PuPuPuC(A/T)(T/A)
GPyPyPy, where Pu = purine and Py = pyrimidine (el-Deiry et
al., 1992). A scan of the HCMV genome shows 21 matches for
this consensus p53-binding site. Allowing for up to three
mismatches to the consensus in an adjacent site, which is often
observed within sites in known p53-responsive genes (Qian et
al., 2002), each of the 21 identified sites had a second site
directly up- or downstream. Table 2 shows the location of the 21
sites within the genome sequence. The sites are grouped
according to the sequence of the four internal base pairs and,
within these four groups, are listed by the open reading frame
(ORF) in which the perfect match lay. The potential ORFs
affected are also included. At the end of the table legend is a list
of several genes that are important for the viral life cycle which
have p53 consensus binding sites located either within or
upstream of their coding regions. These include proteins
involved directly in the replication of the viral DNA (UL44,
UL54, UL57, UL70, and UL105) as well as in the processing
and packaging of the virus (UL56, UL89, UL93, and UL104).
Several genes for structural proteins (including tegument,
capsid, and glycoprotein) may also be subject to p53
transactivation or repression.
Traditionally, groups have assessed binding of specific
transcription factors to their putative binding sites via an in
vitro method called the electromobility shift or EMSA assay.
By comparing migration patterns of the protein through non-
denaturing gels in the presence or absence of DNA containing
a putative binding site, one can ascertain whether the protein
binds to this DNA. Through concentration variations of
specific site and competitor site sequences, one can also
determine binding efficiency and specificity. Although this
method is a good way to determine the possibility of protein
binding, it does not allow one to look at the question in the
context of an in vivo interaction. Alternative to the in vitro
EMSA approach is the chromatin immunoprecipitation (ChIP)
assay. Several groups have successfully used ChIPs analyses
to ascertain whether p53 binds to potential sites in vivo in
response to different types of cellular stress (Dumont et al.,
2003; Kaeser and Iggo, 2002; MacLachlan and El-Deiry,
2003; Szak et al., 2001), and therefore we decided to use thisNotes to Table 2:
The HCMV genomic sequence (AD169) was searched using vector NTI suite for th
and Py = pyrimidine. Twenty-one matches were found. As p53 generally binds to a d
consensus site within the prescribed 13 nucleotides (el-Deiry et al., 1992) either ups
of three mismatches, as is often found in natural sites (Qian et al., 2002). Sites are gr
match (there are four permutations). Secondly, within each permutation, sites are lis
where the potential site resides. If genes overlap at this position, all genes are lis
sequences are given, with the number of nucleotides separating them listed in betwe
of the original site. Small letters were used in the second site sequences to delineate
the presence of these p53-binding sites, either because the sequence lies within the
UL4 = early glycoprotein, UL24, UL25, UL32, UL48, UL71 = tegument protein
reductase large subunit homolog, UL54 = DNA polymerase, UL55 = glycoprotein
DNA-binding protein, UL70, UL105 = helicase/primase components, UL82 = tegu
UL89 = viral endonuclease/terminase subunit, UL97 = virally encoded protein kina
transactivators.methodology in our analysis of p53 binding to the HCMV
genome.
We tested several times pi for binding of p53 to the viral
genome that spanned the IE (4 and 10 h pi), early (24 h pi),
and late (48 h pi) periods of infection. Assays were performed
as described in Materials and methods. Control isotype-
matched IgG Ab precipitations were always performed
alongside precipitations with a p53-specific Ab, as were
precipitations using the p53−/− cells described earlier as
negative controls (Bunz et al., 1998). Non-cross-linked
samples harvested and processed in parallel with the cross-
linked ones served as controls to determine efficient
precipitation of p53 by the p53-specific Ab (data not
shown). We have defined four distinct binding patterns
(Groups 1–4), each of which is represented in Fig. 6. The
first pattern of binding (Group 1 sites) showed no detectable
specific binding at any time pi tested. Group 2 sites showed
binding at 24 h pi, with no detectable subsequent specific
binding at 48 h pi. Group 3 consisted of sites that showed
binding by p53 only at the later time of 48 h pi. Lastly, Group
4 consisted of the sites where p53 was bound at both 24 h and
48 h pi. Groups 1, 3 and 4 each had two subdivisions (a and b);
the latter category of each group contained sites that displayed
amplification of a product in both the p53 Ab and the control
Ab precipitations in FS2 wt fibroblasts. In Group 1, this
control Ab amplification was equivalent to that observed with
p53 Ab and was thus considered negative. All Group 2 sites
also exhibited equivalent control Ab amplification at 48 h pi.
In Groups 3 and 4, the amplification that occurred after p53 Ab
precipitation was always stronger than that from the control Ab
precipitation, and so we considered these positive for binding.
This method of assessment has been used by others (Dumont
et al., 2003; Kaeser and Iggo, 2002; MacLachlan and El-Deiry,
2003; Szak et al., 2001). A summary of the results for 20 of the
21 sites is found in Table 3. We were unable to consistently
amplify product for the remaining site (IGR146) using our
designed primers on control viral DNA, and they were
therefore not included in the analysis. Sites marked with an
* displayed weak positive binding and binding to UL55 was
variable at 48 h pi (denoted with a +).
Since we did not detect any p53-binding at our two earliest
timepoints (4 and 10 h pi), we removed a sample of the total
DNA before treatment with Ab to test the input DNA for thee p53 consensus binding site PuPuPuC(A/T)(A/T)GPyPyPy, where Pu = purine
imeric site, each of these sites was then additionally scrutinized to find another
tream or downstream of the original match. The second site was allowed a total
ouped first by the coding sequence of the internal four base pairs of the original
ted in ascending order of nucleotide binding site, under the vi ral gene product
ted. The consensus binding site match and the second site match nu cleotide
en the sequences. A small u indicates that the second site sequence is upstream
mismatches from the consensus. Lastly, potential genes that may be affected by
gene or directly upstream, are listed below with a description of their function.
s, UL44 = viral DNA polymerase processivity factor, UL45 = ribonucleotide
gB, UL56, UL93, UL104 = DNA packaging proteins, UL57 = single-stranded
ment protein pp71/viral transactivator, UL86 = Major Capsid Protein (MCP),
se (phosphorylates ganciclovir), UL98 = DNAse, UL122/123 = IE72/86 viral
Fig. 6. p53 binds individual sites within the viral genome differentially. FS2 and p53−/− cells were infected at high multiplicity after release from serum starvation
and were harvested at the indicated times for ChIPs analysis. See Materials and methods for details of experiments. No site tested thus far had binding at 4 or 10
h pi. (A) This panel represents the various binding groups found in Table 3. Group 1 sites showed no detectable specific binding at any time pi tested. Group 2
sites showed binding at 24 h pi, with no detectable subsequent binding at 48 h pi. Group 3 consisted of sites that showed binding by p53 only at the later time of
48 h pi. Lastly, Group 4 consisted of the sites where p53 was bound at both 24 h and 48 h pi. Groups 1, 3 and 4 each had two subdivisions (a and b); the latter
category of each group contained sites that displayed amplification of a product in both the p53 Ab and the control Ab precipitations in FS2 wt fibroblasts. In
Group 1b, this control Ab amplification was equivalent to that observed with p53 Ab, and was thus considered negative. In Groups 3b and 4b, the amplification
that occurred after p53 Ab precipitation was always stronger than that from the control Ab precipitation, and so we considered these positive for binding. All
Group 2 sites exhibited equivalent control Ab binding at 48 h pi. In all groups shown in panel A the lanes are defined as follows: Lane 1 = mock infected FS2
precipitated with DO-1 or DO-7 Ab; Lane 2 = mock infected p53−/− precipitated with DO-1 or DO-7 Ab; Lane 3 = infected FS2 precipitated with DO-1 or DO-7
Ab; Lane 4 = infected FS2 precipitated with IgG2a (DO-1) or IgG2b (DO-7) isotype-matched control Ab; Lane 5 = infected p53−/− precipitated with DO-1 or
DO-7 Ab; Lane 6 = infected p53−/− precipitated with IgG2a or IgG2b isotype-matched control Ab; Lane 7 = viral DNA (+) PCR control; Lane 8 = PCR (−)
control (No DNA). (B) This panel represents quantities of the input viral DNA at both 10 and 24 h pi. Small aliquots were removed from samples being
processed for IP. The DNA was phenol-chloroform extracted and ethanol precipitated from the sample. A small proportion (0.25%) of the total DNA samples was
amplified with primers to UL122, which amplifies a product at 24 h pi. The panel lanes are defined as: Lane 1 and 3 = Virally infected FS2; Lane 2 and
4 = Virally infected p53−/−.
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total input DNA were used in identical PCR reactions to
amplify the UL122 site. As can be seen in Fig. 6B, similar
amounts of viral DNA were present at both 10 and 24 h pi,
although binding was only observed at the later timepoint for
this primer pair. This indicated that the ChIPs assays wereselective and that DNA precipitated with the p53-specific Ab
was not nonspecifically binding to either the beads or the Ab
as there was an equivalent amount of viral DNA in all
samples. We can therefore conclude that p53 binds differen-
tially to several sites within the viral genome over the course
of a permissive HCMV infection and may regulate expression
Table 3
p53 binds differentially to 20 sites within the viral genome
Binding groups Binding post infection
4 h 10 h 24 h 48 h
Group 1
A. UL4 No No No No
UL25
UL54
UL64
UL83
B. UL48b No No No No (= to ctrl Ab)
Group 2
UL45
UL48a
UL87⁎ No No Yes No (= to ctrl Ab)
UL105
UL122
Group 3
A. UL88 No No No Yes
UL89⁎
UL123
B. UL57 No No No Yes (N ctrl Ab)
UL97
Group 4
A. UL55⁎,+ No No Yes Yes
UL71⁎
ULS31
B. UL32 No No Yes Yes (N ctrl Ab)
This table illustrates the four patterns of differential binding by p53 to sites
within the viral genome that we have observed in our experiments. Group 1 has
no or very minimal binding at all times tested pi; Group 2 binds at 24 h pi only;
Group 3 binds at 48 h pi alone; and Group 4 was found to have some binding at
both 24 and 48 h pi. An * denotes weak positive binding; a + denotes variable
binding at 48 h pi. See text for additional information.
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viral genes.
Discussion
This paper reports the construction of a panel of mutant p53-
GFP fusion protein constructs used to assess the HCMV-
induced sequestration patterns of mutant versus wt p53-GFP
proteins in the infected cell. Because overexpression of p53 can
potentially lead to arrest, our constructs were engineered to have
expression controlled by the endogenous p53 promoter. Due to
the complexity of p53 protein function and control, we chose to
construct a variety of p53 mutants that affected post-
translational modifications and DNA-binding ability. We
found that our mutants fell into two categories: mutations
made in the post-translational modification sites (phosphoryla-
tion, acetylation, and sumoylation) had no effect on the
sequestration of these proteins after viral infection. Much to
the contrary, mutations to the sequence-specific DNA-binding
domain core negated the ability of these proteins to bespecifically sequestered (see Figs. 2 and 3 and Supplemental
figure).
Our results for mutants in Group One clearly show that
mutation of key post-translational modification sites does not
affect the sequestration of the resultant p53 protein into viral
replication centers. Although we were somewhat surprised by
the overall lack of influence of any of these sites for
sequestration, our results emphasize the conflicting nature of
the current literature with respect to the importance of these
sites for different p53 functions (see Ashcroft et al., 1999;
Xu, 2003 for phosphorylation, Prives and Manley, 2001;
Xu, 2003 for acetylation, and Gostissa et al., 1999;
Rodriguez et al., 1999 for sumoylation sites).
In order to assure that the phosphorylation and acetylation
mutants were not being transported to the replication centers
solely via a heterotetramerization reaction with endogenous wt
p53, we also performed test transfections with a small subset
of Group One mutants and all of the Group Two mutants in a
p53−/− cell line (Fig. 5). The results we obtained were
virtually identical to those observed in wt fibroblasts,
indicating that heterotetramerization was not responsible for
the sequestration we observed in the Group One mutants. In
support of our results, Ashcroft et al. (1999) also observed no
phenotypic changes when transfecting the identical multiple
phosphorylation site mutants into either wt or p53 null mouse
fibroblasts.
In sharp contrast to observations made regarding the post-
translational modification site mutants, mutants with altered
sequence-specific DNA-binding domains showed no specific
sequestration into the replication centers and instead showed a
homogeneous staining pattern over the entire nucleus. These
mutants all expressed full-length proteins in vitro (data not
shown) and in vivo (Fig. 4 and data not shown) and gave
strong GFP+ signals upon transfection/infection (Fig. 2 and
Supplemental figure). It is very clear from the literature that the
ability of p53 to bind in a sequence-specific manner to
promoter sequences of target genes is essential for its function.
All of the DNA-binding domain mutants tested lacked this
binding ability. Although the HCMV IE86 protein can bind to
p53 (at least in vitro and in transient in vivo assays; Bonin and
McDougall, 1997; Muganda et al., 1994, 1998; Speir et al.,
1994; Tsai et al., 1996; Wang et al., 2000) and may play a role
in recruiting/tethering p53 to viral replication centers, we do
not feel that this is the sole mechanism of recruitment. If the
IE86 protein were solely responsible for import, then all of our
mutants should be sequestered equally well, as the IE86-
binding site as mapped by Tsai et al. (1996) (aa 339–363) was
not affected in any of our mutants. Only the DNA-binding
domain mutants were not sequestered, indicating that an intact
domain was required for localization to the centers. This in
turn posed the question of significance of sequence-specific
interaction of p53 with the virus; that is, does the virus use p53
to aid in expression of certain promoters during the course of
infection?
With this question in mind, we undertook a screen of the
HCMV genome and found 21 matches for the consensus p53-
binding site. When we allowed for up to three mismatches,
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within close proximity, either upstream or downstream of the
original match. This list of proteins potentially affected
includes those involved directly in the replication of the viral
DNA (UL44, UL54, UL57, UL70, and UL105) as well as in
the processing and packaging of the virus (UL56, UL89,
UL93, and UL104) and structural components of the capsid,
tegument, and envelope (UL24, UL25, UL32, UL48, UL55,
UL71, UL86).
We have undertaken an extensive study of binding to 20 of
these identified sites using ChIPs analyses in an attempt to
discern potential p53 activity with respect to the viral genome
(the other site did not reproducibly amplify control DNA with
our designed primers). Of these 20, 14 showed differential
binding at some level, while 6 showed no specific binding at
any of the times tested. Binding to several of these sites is
noteworthy. Within the Group 2 sites, binding to UL122 (the
immediate early protein IE86) and to the helicase/primase
component (UL105) should be noted. Binding at 24 h pi
points to an activation role for p53 upon these sites. Lastly,
the UL87 site sits upstream of UL86, which encodes the
major capsid protein (MCP). The binding to this site is
particularly intriguing in light of our recent results comparing
HCMV infection in wt and p53−/− fibroblasts (Casavant et al.,
submitted for publication), where we have observed delays in
accumulation of MCP.
Additional potential activation sites lie within Group 3 with
UL89 (the viral terminase) and UL97 (a viral kinase potentially
involved in remodeling the lamins within the nucleus). The
timing of 48 h pi makes sense for these promoters as this is the
time when HCMV begins replicating in earnest and would need
these proteins. It is interesting to note that an earlier study (Wing
et al., 1998) pointed to the presence of a p53-binding site in the
UL94 promoter that was a “negative regulator” of transcription.
This is the site that we have designated UL89, and, in our hands,
this site is only bound weakly at 48 h pi, and not at early times.
This emphasizes the importance of context as these authors saw
negative regulation only during overexpression studies with
p53, IE86, and a UL94 promoter expression construct
transfected into nonpermissive Saos2 cells and their binding
studies were done in in vitro EMSA experiments.
Possible negative regulation may reside in the binding of
p53 to the Group 3 sites within UL57 (the single stranded
binding protein) and UL123 (the immediate early protein
IE72) as 48 h pi is late for activation of these genes to
commence. All of the sites within Group 4 are also noteworthy
as they are bound by p53 at both 24 and 48 h pi. The ORFs
that are potentially affected by the UL55 site include UL54
(the viral DNA polymerase) and UL55 (glycoprotein gB). The
UL54 gene product, which would certainly be transcribed
relatively early in infection, has also been reported to be
heavily transcribed at later times pi (Kerry et al., 1996). The
UL55 gene product is a structural glycoprotein (gB) found on
the surface of the virion, and thus this ORF would be actively
transcribed late in infection as well. The site in UL71 can
potentially regulate the second component of the helicase/
primase (UL70).The studies presented here emphasize the importance of an
intact DNA-binding domain on the p53 protein for sequestra-
tion of this protein into viral replication centers. Our ChIPs data
point to a regulatory role for p53 in the expression of viral gene
products. DNA microarray analysis of viral gene expression is
now underway comparing expression patterns in both wt and
p53−/− fibroblasts at several times pi. In these studies, we hope
to look at the genes that contain the p53-binding sites as well as
at any genes up- or downstream that might be affected by these
sites. In this way, we hope to gain an idea of the global effects of
p53 on viral gene expression, both positive and negative in
origin.
Materials and methods
Cells and virus growth
KL22 and FS2 primary human foreskin fibroblasts were
isolated from tissue and propagated in Earle's minimal
essential media (MEM) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), L-glutamine (2 mM), penicillin
(200 U/ml), streptomycin (200 μg/ml), amphotericin B (1.5 μg/
ml), and gentamycin sulfate (50 μg/ml). p53−/− telomerase-
immortalized human fibroblasts (Bunz et al., 1998; Wei et al.,
2001) (a kind gift from Dr. John Sedivy, Brown University)
were propagated in DMEM/F12 media supplemented with
7.5% FBS, L-glutamine (2 mM), penicillin (200 U/ml), and
streptomycin (200 μg/ml). Cells were grown in incubators
maintained at 37 °C and 5% CO2. The Towne strain of HCMV
was obtained from the ATCC (#VR 977), propagated under
standard procedures (Tamashiro et al., 1982), and used at a
multiplicity of infection (MOI) of either 0.25 (Effectine
transfections) or 5 (electroporations and ChIPs assays).
Molecular cloning
The pCLNCX-p53pro-p53GFP vector (a kind gift from G.
Wahl, Salk Institute, San Diego) was used as the basis for our
mutagenesis. As it has not previously been described, we
briefly describe this vector's construction here. First, the p53
promoter sequence (Tuck and Crawford, 1989) was inserted
into the multiple cloning site (MCS) of plasmid pBSIIKS
(Stratagene) in the SmaI site. The MCS was then digested
with BssHII (5′ of the p53 promoter sequence), blunted, and a
NotI linker was added. The vector was then redigested with
NotI and SacI (which cuts 3′ to the p53 promoter sequence),
and an approximately 500 bp fragment was isolated contain-
ing the p53 promoter region. Next, the complete cDNA for
p53 (Zakut-Houri et al., 1985) was inserted into the MCS of
pEGFP-1 (Clontech) between the SalI and BamHI sites, in
frame with the GFP coding sequence. This construct was then
digested with SacI (5′ of the gene) and NotI (3′ of the gene)
to liberate an approximately 2 kb fragment. The retroviral
vector pCLNCX (Naviaux et al., 1996) was then digested
within its MCS between the CMV promoter and the 3′ LTR
sequence, and a NotI linker was added to both ends. Lastly,
all three components were ligated together to obtain
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C term, and N + C term phosphorylation mutant constructs
from the Wahl laboratory in the same pCLNCX backbone
(Ashcroft et al., 1999), we carried out the same subcloning
procedure for these constructs as for the wt.
A modified pCDNA3 vector (Invitrogen), which lacked both
the HCMVmajor IE and T7 promoters, was also constructed for
this study. To make this construct, the parental pCDNA3
plasmid was digested with BglII and HindIII, treated with
Klenow to fill in the overhangs, and a 4.5 kb fragment was
isolated and religated to obtain pCDNA3-T7. To construct our
base plasmid for mutagenesis, wtp53pCDNA3-T7, we digested
both the pCDNA3-T7 and pCLNCX-p53pro-p53GFP vectors
with EcoRV and NotI, isolating 4.5 kb and 2.5 kb fragments,
respectively. These fragments were ligated together and
screened for our base construct.
Mutagenesis and verification of clones
Site-directed mutants were generated using the Stratagene
Quickchange kit per manufacturer's instructions. Mutants
were sequenced within the entire p53 portion of the construct
to assure that only the desired single point mutations were
introduced. The p53 coding sequence from the mutagenized
plasmid was then extracted using HindIII (which cuts 5′ of
p53) and AgeI (which cuts between p53 and GFP) to give a
1.2 kb fragment. This fragment was then exchanged with the
identical fragment excised from a freshly cut wtp53pCDNA3-
T7 plasmid that had not been mutagenized. The resulting
plasmids were resequenced to assure that the mutations were
still intact.
Transfection/Infection experiments
Either actively dividing low passage KL22 primary
foreskin fibroblasts or p53−/− fibroblasts were seeded onto
glass coverslips in 60 mm dishes and were allowed to settle
overnight. Approximately 24 h later, cells were transfected
with 1 μg DNA using the Qiagen Effectine reagent (per
manufacturer's instructions). After 16–18 h, the cells were
washed twice with PBS and media was replaced for 2–3 h.
Cells were subsequently asynchronously infected with the
Towne strain of HCMV at an MOI of approximately 0.25.
Inoculum was removed after approximately 4 h, and cells
were allowed to incubate for an additional 96 h before
coverslips were harvested for immunofluorescence analysis.
For electroporation/infection experiments, actively dividing
FS2 fibroblasts were trypsinized and resuspended in MEM
containing 100 mM HEPES pH 7.4 at a concentration of
2.3 × 106 cells/ml. Eight hundred microliters of cells was
electroporated (BTX model ECM630) with 5 μg of plasmid
DNA using the setting of 300 V/75 Ω/2500 μF and seeded
to 2 × 60 mm plates in complete medium. Cells were then
infected at an MOI of 5 approximately 20 h later. Cover-
slips were harvested for sequestration analysis at 48 h pi,
while cells for Western blot analysis were harvested at 96
h pi.Immunofluorescence
Harvested coverslips were washed in PBS prior to fixation
in 3% formaldehyde for 10 min at room temperature (RT)
followed by permeabilization with 1% Triton X-100 for 5
min. The cells were then washed several times with RT PBS.
Coverslips were blocked with 30% FBS in a blocking
solution (PBS with 1% BSA and 0.01% Tween 20) for 15
min then treated with mouse monoclonal antibody (Ab)
against HCMV ppUL44 (#1202S — The Rumbaugh-Good-
win Institute) diluted in blocking solution for 10 min. After
extensive washes in PBS, coverslips were incubated for 10
min with a donkey anti-mouse TRITC-coupled secondary Ab
(Jackson Laboratories) diluted in blocking solution, washed
again in PBS, and mounted in glycerol containing para-
phenylene diamine to block photobleaching. Nuclei were
counterstained with Hoechst dye. For epifluorescent analysis,
cells were examined and photographed on a Nikon Eclipse
E800 fluorescence microscope equipped with a Nikon DXM
camera and Metavue software. Confocal analysis was
performed on a Zeiss LSM5 Pascal laser scanning microscope
equipped with one argon and two HeNe lasers. Images were
captured using an Axiocam HRM camera and LSM5 Pascal
Software Version 3.2.
Western blot analysis
KL22 or p53−/− cells were seeded, transfected, and then
infected as described above. Cells were trypsinized, washed,
counted, and lysed in Laemmli reducing sample buffer (LRSB)
(2% SDS, 10% glycerol, 100 mM DTT, 60 mM Tris pH 6.8,
Bromophenol blue dye, aprotinin, and leupeptin [2 μg/ml each])
at a concentration of 104 cells/μl buffer at 96 h pi. Lysates were
then sonicated, boiled for 5 min, and spun at 15,000 rpm for 10
min at 4 °C to pellet debris. Equivalent amounts of cell lysates
were then loaded onto an 8 or 10% SDS-PAGE gel. Proteins
were transferred to Protran membrane (Schleicher and Schuell),
and blots were probed for p53 (DO-1) followed by a goat anti-
mouse secondary Ab conjugated with horseradish peroxidase
(Amersham). Proteins were visualized using enhanced chemi-
luminescence reagents (Pierce) according to the manufacturer's
instructions.
Sequence analysis
HCMV genomic sequence was downloaded from the
NCBI website (accession number NC_001347, version
NC_001347.2, VRL 21-Jan-2004) into vector NTI suite,
where a search was performed to find exact matches to the
p53-binding sites. Four permutations to the consensus site
were searched, allowing for either an A or T in each internal
position of PuPuPuC(A/T)(T/A)GPyPyPy, where Pu = purine
and Py = pyrimidine (el-Deiry et al., 1992). When an exact
binding site was found, the surrounding region was searched
again for secondary consensus site matches upstream or
downstream of the exact site, allowing for up to 3 mismatches
in this second site (Qian et al., 2002).
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Foreskin fibroblasts and p53−/− cells were seeded at ∼1–
2 × 106 cells per 100 mm tissue culture plates, allowed to settle
2 h, then infected at an MOI of 5 for 2–3 h. The viral media was
then removed, and cells were given fresh media and harvested at
the indicated times. Harvested cells were fixed with 1%
formaldehyde in PBS for 10 min at room temperature. Glycine
was then added to a total concentration of 0.125 M and
incubated for 5 min to stop the cross-linking. Cells were washed
twice with PBS to remove the formaldehyde solution. Two
milliliters of ice-cold PBS containing protease inhibitors (28 μg/
ml aprotinin, 28 μg/ml leupeptin, 1 mM DTT, 80 mM ß-
glycerophosphate, 20 mM sodium fluoride, 1 mM sodium
orthovanadate) was added to the plate, and cells were collected
via scraping. The cell suspensions were then counted and
aliquoted equally among the different groups (∼0.5 × 106) in 1
ml RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS, 50 mM Tris (pH 8), 5 mM EDTA).
The cells were then sonicated at 30% amplitude (Fisher sonic
dismembranator model 500) for 1 min each to shear the
chromosomal DNA into approximately ∼600 bp fragments
(assessed by agarose electrophoresis). Debris was then pelleted
by centrifugation at 13,000 rpm for 10 min at 4 °C. The
supernatant was then removed to a fresh tube and pre-cleared
with 30 μl of a 50% Protein A Sepharose solution for 2 h with
rocking at 4 °C. The samples were then centrifuged for 5 min at
13,000 rpm (4 °C), and the supernatant was transferred to a new
tube. Two micrograms of Ab (p53 DO-1 or DO-7, or normal
mouse isotype-matched control Ab from Santa Cruz Biotech-
nology) was then added, and the samples were rocked overnight
at 4 °C. Dynal beads (M-280 sheep anti-mouse IgG) were
washed in RIPA buffer four times, resuspended in RIPA, and
then added to the incubating samples (∼4 × 106 beads per
sample) where they were rocked at 4° for 1 h. The beads were
removed from the supernatant by concentrating them with the
Dynal particle concentrator (magnet), and supernatant was
aspirated. The beads were then washed twice in RIPA
(+protease inhibitors) followed by 4 washes in IP wash buffer
(100 mM Tris (pH 8.5), 500 mM LiCl, 1% Nonidet P-40, 1%
deoxycholic acid), and finally in RIPA (−NaCl, −PIs) twice
more. Three hundred microliters of cross-linking reversal buffer
(125 mM Tris (pH 6.8), 10% β-mercaptoethanol, 4% SDS) was
then added to the washed bead pellet and boiled for 30 min to
reverse the cross links. After removing the beads from the
supernatant with the magnet, a DNA extraction was performed
on the supernatant. Three hundred microliters of phenol-
chloroform was added to each supernatant, vortexed briefly,
and centrifuged at 13,000 rpm for 5 min. The aqueous layer was
removed, and the DNA precipitated with ethanol. The DNAwas
air dried and dissolved in 20 μl sterile water. PCR amplification
was then performed as described below.
PCR amplification
Primers were designed to be similar in both length and GC
content. Since each primer was designed to flank the bindingsite by at least 100 base pairs, the size of amplified DNA
segments was also similar, ranging from 220 to 400 bp. Due to
the regularity among the primers, we were able to use the same
PCR program for every primer set, with each run consisting of
30 cycles. PCR amplification was done following standard
procedures. Denaturing occurred at 94 °C for 30 s, followed by
a 30 s annealing period at 55 °C, which was followed in turn by
a 30 s extension period at 72 °C. The sequences of specific
primers used are available upon request.
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